Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Down 57.0% in September

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the recipient of a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 37,000 shares, a decrease of 57.0% from the August 31st total of 86,000 shares. Based on an average daily volume of 176,300 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are short sold.

Coeptis Therapeutics Price Performance

Shares of Coeptis Therapeutics stock opened at $0.16 on Friday. The stock’s fifty day moving average is $0.21 and its 200 day moving average is $0.28. Coeptis Therapeutics has a one year low of $0.16 and a one year high of $1.38. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.55 and a current ratio of 0.55. The stock has a market cap of $6.02 million, a P/E ratio of -0.31 and a beta of -0.91.

Coeptis Therapeutics (NASDAQ:COEP) last posted its quarterly earnings data on Friday, August 16th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Sell-side analysts anticipate that Coeptis Therapeutics will post -0.26 earnings per share for the current year.

Institutional Trading of Coeptis Therapeutics

An institutional investor recently raised its position in Coeptis Therapeutics stock. Armistice Capital LLC boosted its holdings in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) by 59.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,520,000 shares of the company’s stock after buying an additional 1,308,000 shares during the period. Armistice Capital LLC owned 10.32% of Coeptis Therapeutics worth $2,759,000 as of its most recent SEC filing. 13.88% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH downgraded shares of Coeptis Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 18th.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.